Panborn: Customized anti-cancer programs with genetic analysis techniques caused a sensation

Introduction: Panbirths fill a market gap in cancer treatment: access to more targeted treatments for patients through all-gene analysis.
According to gene detection technology, using big data algorithm analysis to provide patients with personalized cancer diagnosis and treatment programs of the start-up company "Pansheng son" recently caused a great stir in the international medical academic and investment circlesOn June 1st a report on brain stemglioma, co-chaired by its chief scientist, Yu Hai, and Professor Zhang Wei of Beijing Tiantan Hospital, was published in the world's leading academic journal Nature Genetics, less than half a year after the founding of Panborn.
Panborn focuses on the field of cancerThis is the largest demand in the domestic market, but also the highest technical content of genetic technology applicationsProfessor Bohai is the world's leading expert in the field of genetic diagnosis and treatment of cancer, Ditinguihed Profeor, a professor of excellence at Duke University in the United States, and a winner of the American Cancer Research Association's Team Science AwardAt the end of 2013, Bohai decided to commercialize its familiar, world-class cancer genome research technology and continue to develop new and effective cancer treatment programsWhat is the target market?
"Pansheng" does not produce drugs, but the use of human big data genetic analysis technology, for cancer prevention, diagnosis, treatment, monitoring of the whole process, to provide patients with a complete set of personalized management programs.
There is now a consensus in the scientific community that different genetic mutations cause cancer in the human body or a risk of cancerBrain stem glioma, for example, is an extremely dangerous type of brain cancer and one of the most difficult diseases to tackleThe newly discovered genetic mutation PPM1D can directly lead to the loss of radiotherapy, according to the results just published in the academic journal Nature GeneticsGenomic analysis can help patients avoid useless radiation therapy with high side effects and develop more effective treatment optionsA new type of treatment that can replace radiotherapy and chemotherapy is called targeted therapy, which, like missiles, kills tumor cells withpres without harming normal tissue, controls disease and prolongs lifeThe results of the study of "pan-born children" point the way for targeted therapy.
More than 3 million new cancer patients are added to China each year, and 2.7 million have died, He saidBoth radiation and medication can make patients resistant and ineffective Only by fully understanding the different genetic mutations of each tumor can it be possible to choose the most appropriate one from different treatment options, which is personalized diagnosis and treatment Although the technology is still expensive, the personalized diagnosis and treatment of cancer will gradually become the standard in the field of cancer In the early days of the venture, Bohai met Wang Sizhen, who has many years of experience in Internet and telecommunications operations and financial background Wang SiZhen gaokao had applied for the biology major, but then yin and yang mistakenly changed to study finance, the direction of the venture just in line with his original college entrance examination volunteer.
As one of the co-founders, Wang Sizhen joined the company as CEO in the early stages of team formation, which gave Pansheng a market operation capability that other technology-based home-grown start-ups could not have He has been a business man in the telecommunications consumer goods industry for more than a decade, after successfully exiting his last start-up business, he chose to pursue a career in the health industry, and full-time for the "pan-born" future efforts.
Wang Sizhen revealed that "Pansheng Son" has now completed the Angel Round financing, is expected to complete the construction of the operating platform in the second half of the year, and plans to start round A financing by the end of 2014.
The research on gene diagnostic therapy in Bohai began with brain cancer, but the field of brain cancer is only a breakthrough in the panborn business, and they are applying the most advanced cancer diagnostic analysis technology to all cancer types for all patients.
Wang Sizhen said that "pan-born children" priority to Chinese the most frequent, unique types of tumors, such as in Europe and the United States are not common esophageal cancer, stomach cancer, liver cancer, etc , to help China's largest number of people with cancer access to optimal treatment options.
He said Panborn will transform the world's leading scientific research into a clinical service that truly delivers healthy benefits They will take a three-dimensional marketing combination, with traditional scientific research customers - hospitals and research institutes, but also for cancer patients and healthy people to provide personalized treatment programs, which with the network channels and high-end medical institutions will be one of the effective channels for promotion.